Jun. 15 at 11:35 PM
$TCBP
All I am saying without any prejudice,
I have been positive on GDT cell technology, its role in immunotherapy. My opinion of TC008 still remains positive, even though , the result for cohort A or 1 had been inconclusive so far but the patient in cohort B has a CR.
Cohort A or 1: Relapsed & Refractory AML is almost impossible to cure so far. In clinical trials so far, there have been less than a few CR only to see them Relapse later.
This is been one of my Beef with this CEO for not changing the course of treatment such as MRD AML or cohort B , 3 years ago, while we the retail lost our shirts suffering 4 RSs. if they are successful recruiting a few more MRD patients and show good results this treatment could be used as an adjunct to primary first line treatment for AML. that means being added to 1st line treatment not just for AML . GDT does work.
This is not a pump, No one should buy based on this post. First we need to see if this result stands the test of time & #s.